Navigation Links
Thomson Scientific Publishes its Third Quarter Issue of the Ones to Watch Reviewing the Most Promising Drugs in the Pharmaceutical Pipeline
Date:11/30/2007

ns in blood pressure than either drug alone. This, along with its favorable side-effect profile, should make AZOR an attractive treatment option for patients whose blood pressure does not respond to either component drug in isolation. U.S. approval was granted in September 2007.

While the reason for menopause remains unknown, KV Pharmaceutical believes EvaMist, which takes the third spot on the list, may offer significant advantages to women experiencing menopause. This product is a small, easy-to- use hand-held applicator that delivers a pre-set metered dose via the skin, releasing estradoil into the bloodstream over 24 hours. EvaMist gained FDA approval in July 2007.

The first of two potential treatments for cancer on the list of notable drugs gaining approval this quarter is Yondelis, developed by PharmaMar for patients who have not responded to previous regimens in their treatment of soft tissue sarcoma. Yondelis is the first approved product from PharmaMar, a Spanish biotech specializing in cancer drugs derived from marine organisms and has Orphan Drug status in both the EU and U.S., securing extended protection against generic competition.

The second approval win for Novartis this quarter, Tasigna, is an orally available inhibitor of Bcr-Abl, c-Kit, PDGF-R and related receptor tyrosine kinases for the potential treatment of various types of leukemia. Though the drug has been approved only in Switzerland for chronic myeloid leukemia, it is awaiting approval in the U.S. and Japan and has been recommended for approval across the EU.

Following are the top five drugs in each category of phase changes:

The Five Most Promising Drugs Entering Phase III Trials

* bevasiranib sodium, (Wet AMD), Opko

* recombinant active glucocerebrosidase, (Gaucher's disease), Protalix

* odanacatib, (osteoporosis), Merck & Co

* laquinimod, (multiple sclerosis), Active Biotech/Teva

* elesclomol, (solid tumors), Synta
'/>"/>

SOURCE Thomson Scientific
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine news :

1. Thomson Scientific Predicts Nobel Laureates
2. Thomson Scientific Announces BONDplus for Biological Researchers
3. Hospitals Improve Survival Rates While Treating Sicker Patients Thomson Healthcare Study Shows
4. Thomson Scientific Signs Multi-Year Agreement with The Council for Scientific and Industrial Research (CSIR)
5. Thomson Healthcare Endorsed as Preferred Vendor of Information Products and Services for Virginia Hospitals
6. Thomson Acquires Prous Science
7. Common Early-Warning Symptoms of Ovarian Cancer Identified in CDC/Thomson Healthcare Study
8. Thomson Scientific Ranks Australian Universities and Research Institutes
9. Thomson Healthcare Study Finds That Hospitals Delivering High-Quality Heart Care Are Efficient and Cost Effective, Too
10. Thomson Scientific Launches Confessions ... of a User Campaign Asking Are You the New Face of Research?
11. Contract Renewal Extends Thomson Healthcares Long-Standing Relationship with University Hospitals
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/24/2014)... The Mesothelioma Applied Research Foundation ... on Malignant Mesothelioma from March 2nd through March 4th ... take place on the campus of the National Institutes ... dinner and an awards ceremony, will be held at ... range of topics about pleural and peritoneal mesothelioma, treatments, ...
(Date:11/24/2014)... November 24, 2014 A new ... London's pre-eminent pain-relief service and massage therapy provider, ... Massage (ESM). This newest sports massage ... key difference between traditional sports massage and ESM ... the body's very own "reset button,” and ESM ...
(Date:11/24/2014)... SWAccessControl.com has recently released a new collection of ... company is a leading online supplier in the international market. ... at discounted prices, up to 30% off. , “We are ... time, all of our items are offered at low rates. ... I have confidence in our fresh assortment. You will have ...
(Date:11/24/2014)... CO, and Philadelphia, PA (PRWEB) November 24, 2014 ... provider of care coordination and disease management services ... has chosen to implement Essette’s Medical Management software ... new Essette SaaS platform in a program to ... Essette suite includes Population Health Management, Care Management, ...
(Date:11/23/2014)... Dallas, TX (PRWEB) November 24, 2014 ... Trials Review, H2, 2014" provides data on the ... information and data relating to the clinical trials ... trial numbers and their recruitment status as per ... The databook offers a preliminary coverage of disease ...
Breaking Medicine News(10 mins):Health News:2015 International Symposium on Malignant Mesothelioma Will Take Place at the National Institutes of Health Campus 2Health News:2015 International Symposium on Malignant Mesothelioma Will Take Place at the National Institutes of Health Campus 3Health News:Sports Massage in London by Massaggi Presents New Technique to Reset Muscles, Rapidly Eliminate Pain 2Health News:Sports Massage in London by Massaggi Presents New Technique to Reset Muscles, Rapidly Eliminate Pain 3Health News:SWAccessControl.com Is Happy To Release New Range Of Magnetic Locks 2Health News:ReAdmission Solutions, LLC Selects Essette 2Health News:Aspergillosis Pipeline and Clinical Trials Market (Compnies and Drugs) Review H2 2014 Report at ReportsnReports.com 2Health News:Aspergillosis Pipeline and Clinical Trials Market (Compnies and Drugs) Review H2 2014 Report at ReportsnReports.com 3Health News:Aspergillosis Pipeline and Clinical Trials Market (Compnies and Drugs) Review H2 2014 Report at ReportsnReports.com 4
... March 31 A new study in The ... benefits for nurses and patients when continuous vigilance monitoring ... were definitive," stated Dr. Patrick Sullivan, President and CEO ... an early alert to RNs about potential patient deterioration ...
... , - "Thinking Outside ... , Elsevier, a leading ... in the Elsevier Article 2.0 Contest (, http://www.article20.elsevier.com ... useful solutions for rendering journal articles on the,web. ...
... employers across North Carolina , ... Englewood, CO (Vocus) ... life science careers and information, unveiled the seventh edition of the ... , ,This regional campaign is a promotional effort highlighting biotechnological, pharmaceutical ...
... $25 Monthly Fee for Copayments , ... Mineola, NY ... the nation,s lowest cost provider of merchant services, is pleased to ... doctors, dentists, chiropractors, podiatrists and other health care professionals., , ,The ...
... Government Facilities Offer Greater Work-Life Balance , ... Alpharetta, ... recent LocumTenens.com physician survey, only 11% had not worked ... of respondents, most (82%) said they were interested in trying government ...
... China, March 31 /PRNewswire-Asia-FirstCall/ -- China Sky One,Medical, ... (Nasdaq: CSKI ), a,leading fully integrated ... of China ("PRC"), today announced that it has,cancelled ... a.m. EDT,on March 31, 2009. The Company will ...
Cached Medicine News:Health News:Continuous Vigilance Monitoring Technology Benefits Nurses & Patients 2Health News:Three Prize Winners Awarded in Elsevier's Article 2.0 Contest 2Health News:Three Prize Winners Awarded in Elsevier's Article 2.0 Contest 3Health News:BioSpace Launches the 2009 Bio NC™ Hotbed Campaign 2Health News:EnablePay Announces Special Payments Processing Program for Doctors, Dentists And Other Health Care Professionals 2Health News:Physician Survey Highlights Advantages of Government Locum Tenens Jobs 2Health News:Physician Survey Highlights Advantages of Government Locum Tenens Jobs 3Health News:China Sky One Medical, Inc. Delays Fourth Quarter and Full Year 2008 Earnings Conference Call 2
(Date:11/22/2014)... 2014  Sprout Pharmaceuticals today announced positive preliminary results from ... with flibanserin up to 200 mg at bedtime had no ... the 20 th Annual Fall Scientific Meeting of the ... in Miami . The Phase ... Response Letter and the Formal Dispute Resolution that was filed ...
(Date:11/22/2014)... 21 de noviembre de 2014  BioClinica®, Inc., ... externalizados y tecnologías eClinical, ha indicado un aumento ... inteligente, para el seguimiento basado en el riesgo ... el concepto del seguimiento basado en el riesgo ... visitas de seguimiento o cambio de los métodos ...
(Date:11/22/2014)... , Nov. 21, 2014 MEDITE Group acquired ... nine months and the 3 rd quarter sales ended ... income was $448,000 for the nine months ended September 2014 ... "Even though our 3 rd quarter is usually a ... extends from July into September for many countries worldwide, we ...
Breaking Medicine Technology:Sprout Pharmaceuticals Presents Phase 1 Clinical Trial Data Showing Treatment With Flibanserin Results In No Next-Day Driving Impairment 2Sprout Pharmaceuticals Presents Phase 1 Clinical Trial Data Showing Treatment With Flibanserin Results In No Next-Day Driving Impairment 3El 'seguimiento inteligente' consigue un excelente momento 2El 'seguimiento inteligente' consigue un excelente momento 3CytoCore Inc. / MEDITE Cancer Diagnostics, Inc. Reports Record YTD and 3rd Quarter Sales 2CytoCore Inc. / MEDITE Cancer Diagnostics, Inc. Reports Record YTD and 3rd Quarter Sales 3
... ("Volition" or the "Company"), a life sciences company focused on ... shareholders from Cameron Reynolds, CEO: Dear Shareholders, ... growing and the fact that we have been reaching our ... and look forward to future goals that will continue to ...
... Inovio Pharmaceuticals, Inc. (NYSE Amex: INO ... and infectious diseases, announced today that VGX-3100, its investigational ... by human papillomavirus, was highlighted by Fierce Vaccines ... (see VGX-3100 – Cervical cancer). Inovio is currently ...
Cached Medicine Technology:VolitionRX Limited Issues Update Letter to Shareholders 2VolitionRX Limited Issues Update Letter to Shareholders 3VolitionRX Limited Issues Update Letter to Shareholders 4VolitionRX Limited Issues Update Letter to Shareholders 5Inovio Pharmaceuticals Cervical Dysplasia And Cancer Treatment Highlighted as One of 10 Promising Therapeutic Vaccines; Phase II Clinical Study Currently Enrolling 2Inovio Pharmaceuticals Cervical Dysplasia And Cancer Treatment Highlighted as One of 10 Promising Therapeutic Vaccines; Phase II Clinical Study Currently Enrolling 3Inovio Pharmaceuticals Cervical Dysplasia And Cancer Treatment Highlighted as One of 10 Promising Therapeutic Vaccines; Phase II Clinical Study Currently Enrolling 4Inovio Pharmaceuticals Cervical Dysplasia And Cancer Treatment Highlighted as One of 10 Promising Therapeutic Vaccines; Phase II Clinical Study Currently Enrolling 5Inovio Pharmaceuticals Cervical Dysplasia And Cancer Treatment Highlighted as One of 10 Promising Therapeutic Vaccines; Phase II Clinical Study Currently Enrolling 6
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
Medicine Products: